A Study Assessing KB707 for the Treatment of Locally Advanced or Metastatic Solid Tumors
A phase 1/2 trial of Relatlimab + nivolumab, Pembrolizumab in melanoma, run by Krystal Biotech, Inc., now recruiting.
Overview
A Study Assessing KB707 for the Treatment of Locally Advanced or Metastatic Solid Tumors is a phase 1/2 interventional study registered as NCT05970497 by Krystal Biotech, Inc., with 240 participants planned, started 2023-10-31 and due to reach its primary completion in 2027-07. Interventions recorded: KB707, Opdualag, KEYTRUDA ®( Pembrolizumab). Conditions listed: Cancer, Melanoma Stage III, Melanoma Stage IV, Cutaneous Melanoma. No results are recorded here; the registry entry is the source.
Similar pages
not linked directly; found by shared links- TrialA Study Assessing KB707 for the Treatment of Advanced Solid Tumor Malignancies Affecting the Lungs
Shares Krystal Biotech, Pembrolizumab.
- TrialA Study of Subcutaneous Nivolumab + Relatlimab Fixed-dose Combination (FDC) in Previously Untreated Metastatic or Unresectable Melanoma
Shares Relatlimab + nivolumab, Melanoma.
- TrialA Study to Evaluate Whether Participants With Melanoma Prefer Subcutaneous vs Intravenous Administration of Nivolumab and Nivolumab + Relatlimab Fixed
Shares Relatlimab + nivolumab, Melanoma.
- TrialA Study With Combinations of Anti-LAG-3 and Anti-PD-1 Antibodies in Adult Participants With Advanced or Metastatic Melanoma (Harmony Head-to-Head)
Shares Relatlimab + nivolumab, Melanoma.
- TrialRELATIVITY-098
Shares Relatlimab + nivolumab, Melanoma.
- PairingCaution: LAG-3 blockade outside active disease
Shares Relatlimab + nivolumab, Melanoma.
- PersonHussein A. Tawbi
Shares Relatlimab + nivolumab, Melanoma.
- TrialRELATIVITY-047
Shares Relatlimab + nivolumab, Melanoma.